Vaxart, Inc. – Press Releases

Search

Year

December 02, 2024

Vaxart Completes Enrollment of Sentinel Cohort in Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

SOUTH SAN FRANCISCO, Calif. , Dec. 02, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced completion of enrollment of the sentinel cohort of a Phase 2b clinical trial evaluating Vaxart’s oral pill COVID-19 vaccine candidate against an approved mRNA vaccine comparator.

November 19, 2024

PDF Version

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. , Nov. 19, 2024 (GLOBE NEWSWIRE) -- Vaxart , Inc. (Nasdaq: VXRT) (the “Company” or “Vaxart”) today announced that on November 15, 2024 , the Compensation Committee of the Board of Directors granted inducement equity awards covering an aggregate of 91,500 shares of its

November 13, 2024

PDF Version

Vaxart Provides Business Update and Reports Third Quarter 2024 Financial Results

Expects to complete enrollment of the 400-participant sentinel cohort for the COVID-19 Phase 2b study in November 2024 Solid financial position enables Vaxart to attain multiple regulatory and clinical milestones Conference call today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif. , Nov.

November 07, 2024

PDF Version

Vaxart to Host Third Quarter 2024 Business Update and Financial Results Conference Call on November 13

Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif. , Nov. 07, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the third quarter ended September 30, 2024 , after the market close on Wednesday,

October 24, 2024

PDF Version

Vaxart to Showcase its COVID-19 and Norovirus Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2024

SOUTH SAN FRANCISCO, Calif. , Oct. 24, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it will present research featuring its COVID-19 and norovirus oral pill vaccine candidates at the World Vaccine Congress Europe 2024 taking place in Barcelona, Spain on October 28-31,

October 15, 2024

PDF Version

Vaxart to Present Norovirus Data at IDWeek 2024 Underscoring Commitment to Address Significant Unmet Need

SOUTH SAN FRANCISCO, Calif. , Oct. 15, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it will present research demonstrating the potential of its norovirus oral pill vaccine candidate at IDWeek taking place October 16-19, 2024 , at the Los Angeles Convention Center in Los

September 30, 2024

PDF Version

Vaxart Announces Initiation of Sentinel Cohort for Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

— 400 subject sentinel portion of Phase 2b study will evaluate the safety, immunogenicity and efficacy of Vaxart’s next generation oral pill COVID-19 vaccine compared to an approved mRNA vaccine comparator — — The sentinel cohort is being funded as part of the Phase 2b NextGen COVID-19 clinical

August 30, 2024

PDF Version

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. , Aug. 30, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the “Company” or “Vaxart”) today announced that on August 26, 2024 , the Compensation Committee of the Board of Directors granted inducement equity awards covering an aggregate of 32,250 shares of its

August 28, 2024

PDF Version

Vaxart Announces Publication in Vaccines of Preclinical Data Supporting the Potential of its Mucosal Vaccine Technology Platform in Enabling Therapeutic Vaccination for HPV-Related Cervical Dysplasia

- Data show that Vaxart’s HPV vaccine constructs stimulate specific T cell immune responses, reduce tumor size, and increase survival in an animal model of human papillomavirus (HPV)-related tumorigenesis - - Results suggest that Vaxart’s mucosal vaccine platform holds promise in enabling a novel,

August 08, 2024

PDF Version

Vaxart Provides Business Update and Reports Second Quarter 2024 Financial Results

BARDA Project NextGen contract to support a Phase 2b trial potentially positions Vaxart’s oral pill vaccine platform as a next-generation approach to combating COVID-19 and future pandemic threats Solid financial position enables Vaxart to execute on multiple regulatory and clinical

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Press Releases.

Search